Posted by Ritch on April 14, 2003, at 13:09:54
In reply to Please help with my list of promising future drugs, posted by Shawn. T. on April 13, 2003, at 18:59:16
> I am writing an article about the most promising future drug treatment options for psychiatric disorders. I would like to know if any of you have suggestions that are not already on my rough initial list. I'm interested in drugs that have not yet been marketed. However, theoretical drugs that have not yet been synthesized would not make the list; for example, a 5-HT-moduline blocker wouldn't make it. JR Becker has helped me a bit with this list; I'd like to get more opinions to insure a well rounded list.
>
> 1. CRF1 antagonists (for depression/anxiety)
> 2. AVP V1B receptor antagonists (for anxious-retarded depression). SSR149415 is an example.
> 3. NK1 antagonists aka substance P blockers (for anxiety disorders)
> 4. Benzodiazepine partial agonists (for anxiety disorders and possibly others). Imidazenil and RWJ-51204 are examples.
> 5. Cholecystokinin CCKB antagonists (for panic/anxiety disorders)
> 6. 5-HT1A agonists (these may not make the final cut)
> 7. Melanin-concentrating hormone MCH1 antagonists (perhaps for depression w/hyperphagia). SNAP-7941 is an example.
> 8. One of the 5-HT2C antagonists, perhaps a drug from Servier called agomelatine that is both a 5-HT2C antagonist and melatonin receptor agonist. It seems to be especially useful for people with sleep disturbances.
> 9. PKC alpha blockers (for bipolar disorder). Tamoxifen is an example, but I'd prefer to see something available with fewer side effects.
> 10. AMPA receptor modulators like the Ampakines from Cortex Pharmaceuticals (perhaps for schizoaffective disorders, mild cognitive impairment, and possibly others)
>
> Note that I've removed NMDA antagonists, 5-HT1B ligands, MIF1 analogues, and unreleased dual reuptake inhibitors from the list. I may choose to add the alpha-2-adrenoceptor partial agonist moxonidine (for ADHD) pending my evaluation of how Eli Lilly perceives the drug's potential. I still question the usefulness of glucocorticoid antagonists given the advantages of CRF antagonists, but they'll certainly be useful for Cushing's Syndrome. Note that the article will be posted on my website ( http://www.neurotransmitter.net ).
>
> Thanks for any suggestions,
>
> Shawn
I think it would be interesting to see a cost-competitive 5HT-3 antagonist, or even a 5HT3-antagonist+SRI med. (for anxiety disorders-as an alternative for people who are especially sensitive to SSRI GI side effects such as nausea, diarrhea, and acid reflux).
poster:Ritch
thread:219077
URL: http://www.dr-bob.org/babble/20030411/msgs/219241.html